Glimepirida Ciclum

Glimepirida Ciclum is a prescription oral medication that contains the active ingredient glimepiride. The product is marketed in the European Union and is classified as a sulfonylurea antidiabetic agent. While the specific dosage strength and dosage form are not disclosed, it is intended for oral administration to help manage blood glucose levels in adults with type 2 diabetes mellitus.

Glimepirida Ciclum is indicated for the treatment of type 2 diabetes mellitus as part of a comprehensive diabetes management plan. It may be used when diet, exercise, and other oral agents are insufficient to achieve glycemic control.

- Improves fasting and post‑prandial blood glucose levels. - Can be combined with metformin or other oral antidiabetics. - May be prescribed when lifestyle modifications alone are inadequate. - Used in adults diagnosed with type 2 diabetes. - Supports overall glycemic management alongside diet and exercise.

Glimepirida Ciclum may cause a range of side effects, some of which are more frequently reported than others.

Common: - Mild hypoglycemia (low blood sugar) - Headache - Dizziness - Nausea or abdominal discomfort - Weight gain - Skin rash or itching

Serious: - Severe hypoglycemia requiring assistance - Allergic reactions such as swelling of the face, lips, or throat - Hepatic dysfunction indicated by jaundice - Hematologic abnormalities like leukopenia or thrombocytopenia

Before starting Glimepirida Ciclum, certain precautions should be considered to ensure safe use.

- Assess renal and hepatic function, as impairment may affect drug clearance. - Monitor blood glucose regularly to detect hypoglycemia. - Use cautiously in elderly patients who may be more susceptible to low blood sugar. - Review any history of cardiovascular disease, as sulfonylureas can affect cardiac outcomes. - Avoid use during pregnancy or breastfeeding unless clearly indicated by a physician. - Discontinue if signs of severe allergic reaction appear.

Glimepirida Ciclum can interact with several medications, influencing its efficacy or safety profile.

Avoid: - Other sulfonylureas or insulin, which may increase the risk of hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise glimepiride levels. - MAO‑B inhibitors, which may potentiate hypoglycemic effects.

Use with caution: - Beta‑blockers, which can mask hypoglycemia symptoms. - Thiazide diuretics, as they may affect glucose tolerance. - NSAIDs and aspirin, which can impair renal function and alter drug clearance.